Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells $338,416.92 in Stock

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CEO Dinesh Ph Patel sold 4,068 shares of the firm’s stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $83.19, for a total value of $338,416.92. Following the completion of the sale, the chief executive officer directly owned 574,505 shares of the company’s stock, valued at approximately $47,793,070.95. This trade represents a 0.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Protagonist Therapeutics Stock Down 2.5%

NASDAQ:PTGX opened at $79.73 on Friday. The firm’s fifty day simple moving average is $86.33 and its 200-day simple moving average is $72.53. The stock has a market cap of $4.98 billion, a PE ratio of 128.60 and a beta of 2.26. Protagonist Therapeutics, Inc. has a fifty-two week low of $33.70 and a fifty-two week high of $96.54.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.03). Protagonist Therapeutics had a return on equity of 6.86% and a net margin of 21.94%.The company had revenue of $4.71 million for the quarter, compared to analysts’ expectations of $5.41 million. Equities analysts anticipate that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. Citizens Jmp raised their price objective on Protagonist Therapeutics from $69.00 to $102.00 and gave the company a “market outperform” rating in a research note on Friday, November 7th. BMO Capital Markets reissued an “outperform” rating on shares of Protagonist Therapeutics in a research report on Monday, October 13th. HC Wainwright reissued a “buy” rating and set a $80.00 price objective on shares of Protagonist Therapeutics in a research note on Wednesday, October 8th. JPMorgan Chase & Co. lifted their target price on shares of Protagonist Therapeutics from $68.00 to $81.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Finally, Citigroup increased their price target on Protagonist Therapeutics from $98.00 to $115.00 and gave the stock a “buy” rating in a research note on Monday, December 8th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, Protagonist Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $86.77.

Hedge Funds Weigh In On Protagonist Therapeutics

Large investors have recently bought and sold shares of the stock. Farther Finance Advisors LLC boosted its holdings in shares of Protagonist Therapeutics by 110.6% in the 4th quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock valued at $26,000 after purchasing an additional 156 shares during the last quarter. Salomon & Ludwin LLC purchased a new position in shares of Protagonist Therapeutics in the 3rd quarter worth $29,000. FNY Investment Advisers LLC purchased a new stake in Protagonist Therapeutics during the second quarter valued at about $27,000. Bessemer Group Inc. increased its stake in Protagonist Therapeutics by 171.0% during the second quarter. Bessemer Group Inc. now owns 504 shares of the company’s stock worth $28,000 after acquiring an additional 318 shares during the last quarter. Finally, EverSource Wealth Advisors LLC raised its holdings in shares of Protagonist Therapeutics by 138.9% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 540 shares of the company’s stock worth $36,000 after purchasing an additional 314 shares during the period. Hedge funds and other institutional investors own 98.63% of the company’s stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.